- Health
- SEE MORE
- classical
- general
- talk
- News
- Family
- Bürgerfunk
- pop
- Islam
- soul
- jazz
- Comedy
- humor
- wissenschaft
- opera
- baroque
- gesellschaft
- theater
- Local
- alternative
- electro
- rock
- rap
- lifestyle
- Music
- como
- RNE
- ballads
- greek
- Buddhism
- deportes
- christian
- Technology
- piano
- djs
- Dance
- dutch
- flamenco
- social
- hope
- christian rock
- academia
- afrique
- Business
- musique
- ελληνική-μουσική
- religion
- World radio
- Zarzuela
- travel
- World
- NFL
- media
- Art
- public
- Sports
- Gospel
- st.
- baptist
- Leisure
- Kids & Family
- musical
- club
- Culture
- Health & Fitness
- True Crime
- Fiction
- children
- Society & Culture
- TV & Film
- gold
- kunst
- música
- gay
- Natural
- a
- francais
- bach
- economics
- kultur
- evangelical
- tech
- Opinion
- Government
- gaming
- College
- technik
- History
- Jesus
- radio
- movies
- services
- Church
- podcast
- Education
- international
- Transportation
- Other
- kids
- podcasts
- philadelphia
- Noticias
- love
- sport
- Salud
- film
- and
- 4chan
- Disco
- Stories
- fashion
- Arts
- interviews
- hardstyle
- entertainment
- humour
- medieval
- literature
- alma
- Cultura
- video
- TV
- Science
- en
Advanced Antibody Discovery Platform Generates COVID-19 Antibody Therapy with Ian Chan Abpro
Ian Chan, CEO, Abpro is developing a drug which is a COVID-19 neutralizing antibody that has demonstrated strong binding affinity for COVID-19 in a Phase 2/3 global trial. Using the Diverse Immune Platform, an advanced antibody discovery platform, Abpro is drawing on years of successful work developing neutralizing monoclonal antibody therapies for treating traditionally difficult to access cancers, eye disease and autoimmune diseases.\xa0 In addition to vaccines, COVID-19 therapeutics are essential for keeping the disease from progressing particularly for those most at risk.
@abpro #COVID19 #antibodytherapies #monoclonalantibodies